Phase 2 Ovarian Cancer Trial, Recruiting NCT04469764 Sponsor: Jonsson Comprehensive Cancer Center Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 2 Ovarian Cancer Trial, Recruiting

NCT04469764
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with ovarian cancer (including fallopian tube or primary peritoneal cancer) or endometrial (uterine) cancer, confirmed by a lab test on a tissue sample.
  • For ovarian cancer: A specialist medical review panel has looked at your stored tumor tissue using standard genetic testing and found certain features suggesting a specific cell growth pathway (called CDK4/6) is active.
  • For endometrial cancer: A specialist medical review panel has confirmed your tumor is of a specific type (endometrioid), shows positive hormone receptor activity, and does not have certain genetic changes (CCNE amplification or RB loss) based on standard genetic testing of your stored tumor tissue.
  • You have had at least one round of chemotherapy in the past for recurrent ovarian or endometrial cancer.
  • If you had chemotherapy before joining, most side effects have cleared up (with the exception of hair loss or certain nerve-related symptoms), and it has been at least 21 days since your last chemotherapy treatment.
  • If you had radiation therapy before joining, you have fully recovered from its side effects and it has been at least 14 days since your last radiation treatment.
  • You are able to swallow tablets or capsules by mouth.
  • You are generally able to carry out some daily activities — not completely bedridden (confirm with trial site what level of daily functioning is required).
  • You are willing and able to attend scheduled appointments, follow the treatment plan, and complete required tests and procedures.
  • You have given written consent to participate after being informed about the study.
  • Your blood counts and organ function meet certain minimum levels based on recent blood tests, including healthy enough levels of white blood cells, platelets, hemoglobin (red blood cells), and liver function (confirm specific numbers with trial site).
  • If you could potentially become pregnant, you have had a negative pregnancy test within 7 days before starting treatment, and you agree to use a highly effective form of contraception during the study and for 3 weeks after your last dose of the study drug.

Who may not be able to join:

  • You are expected to need major surgery (for example, for a bowel blockage) or radiation therapy during the trial.
  • You have been diagnosed with another cancer in the last 5 years — exceptions may include certain treated skin cancers or very early-stage cervical or breast cancer (confirm with trial site).
  • You have received chemotherapy, surgery, blood transfusions, or another experimental treatment within the 3 weeks before joining the trial.
  • In the past 6 months, you have had a heart attack, severe chest pain, heart bypass surgery, serious heart failure, stroke, mini-stroke, or a blood clot in the lungs.
  • You have unstable cancer that has spread to the brain, or cancer affecting the lining around the brain and spinal cord.
  • You are currently pregnant or breastfeeding.
  • You are able to become pregnant but are not willing to use an effective form of contraception (such as a non-hormonal IUD, condoms, complete abstinence, or a vasectomized partner).
  • You have serious ongoing health conditions that could make participation unsafe — for example, certain lung diseases, severe breathing problems, a history of major stomach or bowel surgery, Crohn's disease, ulcerative colitis, or a long-term condition that already causes significant diarrhea.
  • You currently have an active serious infection requiring IV antibiotics, a fungal infection, HIV, or active hepatitis B or C.
  • You have a personal history of fainting due to a heart problem, dangerous heart rhythm problems, or sudden cardiac arrest.
  • You are currently taking or regularly eating certain foods or medications that strongly interfere with how the study drug is processed in the body — including grapefruit juice and a number of specific prescription medications (confirm the full list with the trial site).
  • You have any other serious medical or mental health condition, or unusual lab results, that the trial doctor believes would make participation unsafe or affect the trial results.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Gottfried E Konecny, UCLA / Jonsson Comprehensive Cancer Center

Phone: 310 825-7028

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Jonsson Comprehensive Cancer Center
Registry
ClinicalTrials.gov
Start date
16 October 2020
Est. completion
1 July 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Proportion of patients who are progression-free

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov